3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
29
Carcinoma, Transitional Cell
25
Urinary Bladder Neoplasms
24
Neoplasms
22
Carcinoma, Merkel Cell
20
Neoplasm Metastasis
18
Carcinoma, Renal Cell
17
Colorectal Neoplasms
16
Breast Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
15
Ovarian Neoplasms
14
Triple Negative Breast Neoplasms
11
Pancreatic Neoplasms
9
Melanoma
9
Head and Neck Neoplasms
8
Stomach Neoplasms
7
Recurrence
6
Carcinoma, Hepatocellular
6
Ureteral Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Urethral Neoplasms
4
Sarcoma
4
Neuroendocrine Tumors
4
Leukemia, Myeloid, Acute
4
Glioblastoma
4
Carcinoma, Squamous Cell
4
Uterine Cervical Neoplasms
3
Turcot syndrome
3
Skin Neoplasms
3
Interventions
Gemcitabine
3
130-nm albumin-bound paclitaxel
2
sintilimab
1
nimotuzumab
1
avelumab
1
Taxes
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Hydroxychloroquine
1
Fluorouracil
1
Capecitabine
1
Antineoplastic Agents
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Cancer Resectable
×
avelumab
×
Clear all
NCT03344172
2020-05-14
17-134
University of Pittsburgh
Phase 2
Terminated
32 enrolled
14 charts